The Utility of Pomalidomide in R/R Multiple Myeloma

Publication
Article
Special ReportsB-Cell Malignancies
Volume 1
Issue 1

Manish Sharma, MD, from the Kimmel Cancer Center at Jefferson, comments on the use of pomalidomide in relapsed/refractory multiple myeloma.

Manish Sharma, MD, from the Kimmel Cancer Center at Jefferson, comments on the use of pomalidomide in relapsed/refractory multiple myeloma.

In an updated analysis of the phase III MM-003 trial, Celgene International Sarl reported on a new progression-free survival analysis and final overall survival.Click here to read more > >

Recent Videos
1 expert in this video
1 expert in this video
4 experts are featured in this series.
1 expert in this video
1 expert in this video
Related Content